Please try another search
For the three months ended 31 March 2022, CUREXO INC. revenues increased from W5.99B to W14.72B. Net loss decreased 74% to W410.1M. Revenues reflect Trade Segment increase from W3.36B to W8.2B, Medical Device Segment increase from W659.9M to W4.18B, Publishing Segment increase of 19% to W2.34B. Lower net loss reflects Medical Device Segment loss decrease of 74% to W439.4M, Trade Segment income totaling W165.4M vs. loss of W221.5M.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 14717.49 | 15024.32 | 10311.62 | 11469.33 |
Gross Profit | 3098.12 | 3432.68 | 1889.02 | 2593.3 |
Operating Income | 120.97 | -2723.27 | -849.55 | 141.91 |
Net Income | -410.09 | -593.18 | -1084.04 | 894.46 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 60371.4 | 61305.98 | 61291.97 | 62682.54 |
Total Liabilities | 17864.86 | 18404.31 | 17993.83 | 18300.37 |
Total Equity | 42506.55 | 42901.67 | 43298.14 | 44382.18 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -4623.06 | -8742.05 | -8976.19 | -3497.71 |
Cash From Investing Activities | 4261.44 | -5925.98 | -5618.81 | -10892.92 |
Cash From Financing Activities | -58.07 | 14726.35 | 14784.64 | 14841.99 |
Net Change in Cash | -431.22 | 68.46 | 199.71 | 456.05 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review